CDK4/6 inhibitors in the treatment of metastatic breast cancer: Focus on toxicity and safety-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

CDK4/6 inhibitors in the treatment of metastatic breast cancer: Focus on toxicity and safety

Published:2023-12 Issue:6 Volume:50 Page:131-139
ISSN:0093-7754
Container-title:Seminars in Oncology
language:en
Short-container-title:Seminars in Oncology

Author:

Wekking Demi^ORCID,Lambertini Matteo,Dessì Mariele,Denaro Nerina,Bardanzellu Fabio,Garrone Ornella,Scartozzi Mario,Solinas Cinzia

Publisher

Elsevier BV

Reference80 articles.

1. FDA approval summary: abemaciclib with endocrine therapy for high-risk early breast cancer;Royce;J Clin Oncol,2022

2. Ribociclib and endocrine therapy as adjuvant treatment in patients with HR+/HER2- early breast cancer: Primary results from the phase III NATALEE trial;Slamon;J Clin Oncol,2023

3. Meta-analysis of selected toxicity endpoints of CDK4/6 inhibitors: palbociclib and ribociclib;Costa;Breast,2017

4. CDK4/6 inhibitors in metastatic breast cancer, a comparison of toxicity and efficacy across agents in a real-world dataset;Buller;J Oncol Pharm Pract,2023

5. CDK4/6 inhibitors in breast cancer: differences in toxicity profiles and impact on agent choice. A systematic review and meta-analysis;Onesti;Expert Rev Anticancer Ther,2021

Cited by 4 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Dose reduction and discontinuation due to the combination of CDK4/6 inhibitors and endocrine drugs: a systematic review and meta-analysis;European Journal of Clinical Pharmacology;2024-09-13

2. A double-blind, placebo-controlled, randomized multiple dose phase 1b trial of a CDK4/6 inhibitor, TCK-276, in patients with active rheumatoid arthritis;Rheumatology;2024-07-13

3. Real-World Experience among Elderly Metastatic Breast Cancer Patients Treated with CDK4/6 Inhibitor-Based Therapy;Cancers;2024-04-30

4. A contemporary review of breast cancer risk factors and the role of artificial intelligence;Frontiers in Oncology;2024-04-18

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3